With this expansion, BostonSight reinforces its commitment to advancing care for patients with severe ocular surface disease and irregular corneas.

Sherrol A. Reynolds, OD, FAAO, details how NOA's history impacts its vision for the future.

Data used in the post hoc analysis were from 56 parameters from 4 testing modalities obtained in a multicenter US trial (NCT03197870).

Increased amounts of time spent in physical activity are independent predictors of a slower rate of visual field mean deviation loss in patients with primary open angle glaucoma.

The net plastic neutral contact lens initiative is part of CooperVision’s partnership with Plastic Bank.

One in 3 children worldwide has myopia, and the prevalence is rising so steadily that if it continues as predicted, there will be more than 740 million pediatric cases by 2050.

Boston event will shed light on cerebral/cortical visual impairment (CVI), a leading cause of pediatric blindness

A rare case of tubulointerstitial nephritis and uveitis syndrome in a teenager highlights the importance of multidisciplinary diagnosis and management.

In a climate of shrinking reimbursements and rising costs, finding your niche isn’t just smart—it’s essential.

New findings confirm TearCare's long-term effectiveness for dry eye disease, showing significant patient improvements with minimal treatments over 2 years.

Rachelle Lin, OD, MS, FAAO, has refined her passions for academia, teaching, low vision practice, and advocacy work to build out a well-rounded career.

Ocular salvage and preservation of vision are essentially dependent on early diagnosis, and several studies have been conducted to identify the factors leading to delayed diagnosis at presentation.

TearCare is associated with greater health utility over time but also resulted in significant cost savings compared with CsA.

Specialty care is always needed in any field, and myopia control is no exception.

With FDA approval of LENZ Therapeutics’ Vizz (LNZ100), optometrists now have a daily, non-invasive treatment option for presbyopia, giving patients more freedom and clinicians greater flexibility in care.

The planned acquisition of STAAR includes the EVO family of lenses (EVO ICL) for vision correction for patients with moderate to high myopia with or without astigmatism.

Diagnostic tools, therapeutic innovations such as anti-vascular endothelial growth factor (VEGF) therapies, and supportive technologies to manage vision loss form the myopic macular degeneration market.

Integrating IRIS technologies will allow Topcon to improve retinal disease diagnostics and referrals from primary care providers.

Better best-corrected visual acuity values and baseline thicker ganglion cell layer and retinal nerve fiber layer at ocular coherence tomography measurements were found to be the key predictive factors.